P2613 - Cardiovascular Disease Risk Improvement With Semaglutide in Patients With Obesity: A Multi-Centered Study

Award: Presidential Poster Award

Wissam Ghusn, MD¹, Diego Anazco, MD¹, Sima Fansa, MD¹, Elif Tama, MD², Alan De La Rosa, MD¹, Bryan Nicolalde, MD¹, Lizeth Cifuentes, MD¹, Daniel Sacoto, MD¹, Alejandro Campos, MD¹, Fauzi Feris, MD¹, Khushboo Gala, MBBS¹, Gerardo Calderon, MD¹, Anas Hashem, MD¹, Maria Daniela. Hurtado, MD, PhD², Andres Acosta, MD, PhD^1
1Mayo Clinic, Rochester, MN; ²Mayo Clinic, Jacksonville, FL

Introduction: Obesity is a major risk factor for the development of dyslipidemia, type-2 diabetes mellitus (T2DM), hypertension (HTN), and obstructive sleep apnea. These comorbidities are associated with an increased risk of cardiovascular disease (CVD), representing the leading cause of death globally. Hence, there is a significant need to prevent CVD by targeting excess adiposity in patients with obesity. Semaglutide is a recently approved anti-obesity medication whose cardiovascular impact in patients with and without T2DM is not well established. We aim to study the real-world effect of semaglutide use on the risk of CVD in patients with overweight or obesity.

Methods: We performed a multicenter retrospective study of patients with a body-mass index (BMI)≥ 27 kg/m². We collected data to calculate the 10-year atherosclerotic cardiovascular disease (10-year ASCVD) risk at baseline and 1 year after semaglutide initiation. Our primary end point included calculating the difference in ASCVD score between baseline and after 1 year of starting semaglutide. Secondary outcomes included total body weight loss percentage (TBWL%) and change in blood pressure, HbA1c, fasting glucose, lipid panel, and HTN medications. We used matched paired t-test and Bowker’s test to compare continuous and categorical variables at baseline and 1 year, respectively. Data are presented in means ± standard deviation.

Results: We included 93 patients in the analysis: 69% female, mean age 55.0± 8.1, 91% white, mean BMI 39.8± 8.6 kg/m² (Table 1). There was a significant decrease in the 10-year ASCVD risk between baseline and 1 year: 7.6% vs 6.3%, mean difference of 1.38%, p< 0.001, n=93 (Figure 1A). The following parameters decreased significantly: blood pressure by 9.3/4.9 mmHg (n= 93; p< 0.001 for systolic and diastolic; Figure 1B), total cholesterol by 9.5 mg/dL (n=93; p=0.008); LDL by 6.6 mg/dL (n=93; p= 0.04), triglycerides by 20.0 mg/dL (n=93; p=0.01; Figure 1C), fasting glucose by 23.0 mg/dL (n= 64; p=0.003), and HbA1c by 0.72% (n=54; p< 0.001; Figure 1D). The TBWL% associated with semaglutide use at 12 months was 10.9% (n=41; p< 0.001 from baseline).

Discussion: The use of semaglutide in patients with overweight or obesity is associated with a decrease in the 10-year ASCVD risk. This decrease may translate into decreased cardiovascular morbidity and mortality risks.



Disclosures:


Wissam Ghusn, MD¹, Diego Anazco, MD¹, Sima Fansa, MD¹, Elif Tama, MD², Alan De La Rosa, MD¹, Bryan Nicolalde, MD¹, Lizeth Cifuentes, MD¹, Daniel Sacoto, MD¹, Alejandro Campos, MD¹, Fauzi Feris, MD¹, Khushboo Gala, MBBS¹, Gerardo Calderon, MD¹, Anas Hashem, MD¹, Maria Daniela. Hurtado, MD, PhD², Andres Acosta, MD, PhD¹. P2613 - Cardiovascular Disease Risk Improvement With Semaglutide in Patients With Obesity: A Multi-Centered Study, ACG 2023 Annual Scientific Meeting Abstracts. Vancouver, BC, Canada: American College of Gastroenterology.